Comparison of in vitro activity of the nitroimidazoles delamanid and pretomanid against multidrug-resistant and extensively drug-resistant tuberculosis

Eur J Clin Microbiol Infect Dis. 2019 Jul;38(7):1293-1296. doi: 10.1007/s10096-019-03551-w. Epub 2019 Apr 5.

Abstract

Delamanid exhibited greater in vitro potency than pretomanid against multidrug-resistant (MDR-) and extensively drug-resistant tuberculosis (XDR-TB) isolates. The pretomanid minimum inhibitory concentration (MIC) values of four MDR-TB isolates were found to be resistant to delamanid ranging from 0.031 to 0.063 mg/L. A novel nonsynonymous mutation within the fbiA gene (Glu249Lys) may be contributing to high-level resistance to delamanid and pretomanid in Mycobacterium tuberculosis.

Keywords: Delamanid; Minimum inhibitory concentration; Mycobacterium tuberculosis; Pretomanid; Susceptibility.

Publication types

  • Comparative Study

MeSH terms

  • Antitubercular Agents / pharmacology*
  • Bacterial Proteins / genetics
  • Drug Resistance, Multiple, Bacterial / genetics*
  • Extensively Drug-Resistant Tuberculosis / microbiology
  • Microbial Sensitivity Tests
  • Mutation
  • Mycobacterium tuberculosis / drug effects*
  • Mycobacterium tuberculosis / genetics
  • Nitroimidazoles / pharmacology*
  • Tuberculosis, Multidrug-Resistant / microbiology

Substances

  • Antitubercular Agents
  • Bacterial Proteins
  • Nitroimidazoles
  • pretomanid